The presently-disclosed subject matter relates to compositions and methods for treating autism spectrum disorders.
Autism Spectrum Disorder (ASD) is a common neurodevelopment disorder characterized by deficits in language and social development and excessive repetitive behaviors, and is commonly associated with cognitive disabilities.
Both genetic and environmental factors can influence risk for autism spectrum disorder (ASD). The longest standing biochemical finding associated with ASD is hyperserotonemia, or elevated blood serotonin (5-HT) levels, which are found in 25-30% of ASD subjects.
Hyperserotonemia is unique to autism as opposed to other developmental disorders10, 11 and is known to be highly heritable, similar to ASD itself.12, 13 Since platelets protect 5-HT from metabolism and clearance, the majority of whole blood 5-HT is found in platelets, and whole blood 5-HT levels are correlated with platelet SERT activity.14-16 SERT is a Na+/Cl−-dependent, high affinity transporter for 5-HT and is the primary means by which 5-HT signaling within the CNS and periphery is controlled.17 Research demonstrates that SERT trafficking and catalytic function are highly regulated, including the control of transporter surface trafficking, phosphorylation states, membrane compartmentalization and 5-HT affinity, each of which can lead to changes in 5-HT clearance rates.18, 19 SERT is phosphorylated under basal conditions, as assessed in transfected cells and nerve terminal preparations, and phosphorylation can be further modulated by 5-HT.20 SERT phosphorylation is augmented through the activation of PKC, PKA, PKG1α,19, 21 and the activation of p38α MAPK.8, 9 Although there are currently four known, distinct isoforms of p38 MAPK, p38α MAPK is believed to be the specific isoform involved in the modulation of SERT activity.22, 23 Signaling involving these pathways also rapidly modulates the activity and/or surface expression of SERT, effects that play a key role in the rapid regulation of 5-HT signaling in the CNS.
Alterations in SERT expression and function have been linked to various neuropsychiatric disorders including depression, anxiety, obsessive compulsive disorder, and ASD.24, 25 Recently, five rare, gain of function (GOF) genetic variants in SERT (gene SLC6A4) have been linked to ASD.24 One of these ASD-associated GOF variants, Gly56Ala, was found to be overtransmitted in ASD, display a male gender bias and to be associated with rigid-compulsive and sensory aversive traits in ASD cohorts.24 Further characterization found the Ala56 variant confers a high affinity state (decreased Km) of SERT for 5-HT, without concomitant changes in 5-HT capacity (same Vmax) or increased surface expression of the transporter.9 Additionally, the SERT Ala56 variant is insensitive to the normal transport stimulatory properties of p38 MAPK activation and results in SERT hyperphosphorylation in vitro.9, 26
In vivo characterization of SERT Ala56 knock in mice27 has revealed that these mice display several phenotypes typical of ASD such as hyperserotonemia, repetitive behaviors and deficits in social interactions and communication.8 Specifically, SERT Ala56 mice display social deficits in the Tube Test for Social Dominance and the Crawley Three Chamber Social Interaction test as compared to SERT Gly56 littermates.8 SERT Ala56 mice also display abnormal repetitive behavior (assessed by hanging bouts from wire cage lids) in their home cage environments and have deficits in stress-induced ultrasonic vocalization (USV) as pups.8 Additionally, SERT Ala56 mice have increased SERT-dependent 5-HT clearance as assessed by in vivo chronoamperometry and 5-HT2A and 5-HT1A receptor hypersensitivity as assessed by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head twitch and 8-hydroxy-2-(di-n-propylamino)-tetraline (8-OH-DPAT)-induced hypothermia, respectively.8 Notably, SERT Ala56 mice exhibit elevated levels of basal SERT phosphorylation, an effect that is dependent upon the activity of p38 MAPK, a known regulator of SERT function.8
Activation of p38 MAPK can arise from a myriad of physiologic and environmental factors including inflammation and increases in proinflammatory cytokine expression, UV light and reactive oxygen (ROS) and reactive nitrogen species (RNS).28, 29 Additionally, activation of the α isoform of p38 MAPK is involved in innate immune system responses to these stimuli,28 an effect that has been linked to increased CNS SERT uptake.30, 31 Previous studies have revealed a distinct pathway by which increases in IL-1R1-mediated signaling stemming from activation of the innate immune system evokes p38α MAPK-dependent increases in SERT activity in vitro and in vivo.30, 31 A distinct regulation of SERT by p38α MAPK in the context of social defeat stress has also been shown, providing evidence that environmental perturbations can regulate p38α MAPK and modulate the activity of SERT within the CNS.23 Furthermore, direct overexpression of IL-1β in the dorsal raphe alters anxiety behaviors in mice, an effect reversed by selective serotonin reuptake inhibitors, providing evidence that these effects are mediated by increased SERT activity.32
Until lately there was a dearth of selective p38 MAPK inhibitors that specifically targeted the α-isoform of p38 MAPK. Recently, a series of highly selective, brain-penetrant, p38 MAPK inhibitors were developed with evidence accruing to support utility in brain injury models (See, e.g., Watterson et al. 2014; International Patent Application Publication No. WO 2014/145485). Co-cystallography studies were utilized to experimentally confirm that a selective p38 MAPK inhibitor, known as MW108, occupies the active site of p38α MAPK and in vivo treatment with the inhibitor was shown to attenuate lipopolysaccharide (LPS)-induced increases in IL-1β within the CNS.41
Interestingly, aberrations in immune system function have repeatedly been found in clinical ASD cohorts33, 34 (including increases in IL-1β),35 in addition to various environmental and genetic rodent models of ASD.36-38 Environmentally-induced models of ASD, such as the maternal immune activation (MIA) model, have revealed long-lasting immune system dysregulation in the offspring of MIA dams.5, 37, 39 Furthermore, previous studies have revealed that MIA offspring have 5-HT2A hypersensitivity, similar to that found in SERT Ala56 mice.8, 40 Combined, these studies provide evidence for the proposal that the dysregulation of 5-HT signaling may be a convergent theme between various models of ASD.
The current prevalence of ASD in the United States population is estimated to be 1 in 68 children, approximately 50% of whom present with below average intellectual ability.1 As ASD has no known cure, lifelong support is the norm. The economic burden to the family and society for such care is substantial, with estimates indicating support for an individual with ASD in the United States over the course of their lifespan to be $2.4 million.2 Compounding these problems are woefully inadequate pharmacotherapies that treat the core deficits of ASD. Owing in part to a still limited understanding of the mechanistic basis for ASD, treatments are lacking for the core symptoms of the disorder.
The current treatment options for ASD are very limited. There are no drugs currently available to treat the primary symptoms of ASD, such as social deficits. Two currently available antipsychotic drugs, risperidone and aripiprazole, are FDA approved for use in ASD patients. Neither of these ameliorates the primary symptoms associated with ASD including the social and communication deficits or repetitive behaviors.
Accordingly, there remains a need in the art for effective compositions and methods for the treatment of ASD, which treat the primary symptoms of ASD, such as social deficits.
The presently-disclosed subject matter meets some or all of the above-identified needs, as will become evident to those of ordinary skill in the art after a study of information provided in this document.
The present inventors contemplate that in both genetic and environmental models of ASD, immune abnormalities as noted above and increased inflammation could drive the activation of p38α MAPK, thereby modulating SERT activity and 5-HT signaling within the CNS, an effect that manifests as the neurobiological and behavioral abnormalities relevant to ASD.
Proposed herein are compositions and methods for treating ASD using a specific p38 MAPK inhibitor. It is proposed herein that p38α MAPK, activated by genetic and/or environmental factors, results in alterations in SERT activity, 5-HT signaling and behavior, including those present ASD, as modeled in SERT Ala56 mice. It is contemplated that targeting p38α MAPK through the use of CNS-penetrant, orally-bioavailable inhibitors results in the reversal of ASD-like phenotypes.
The presently-disclosed subject matter includes a method of treating ASD and/or a symptom thereof, which involves administering to a subject in need of treatment an effective amount of a composition comprising the compound of formula (I)
wherein
In some embodiments of the method, R3 is naphthyl, quinolinyl. Isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D; and wherein said indolyl is not indol-4-yl.
In some embodiments of the method, R3 is naphthyl, quinolinyl, isoquinolinyl, or indol-5-yl, wherein said naphthyl, quinolinyl, isoquinolinyl or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D.
In some embodiments of the method, R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl, wherein said naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D.
In some embodiments of the method, R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl, wherein said naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl is optionally independently substituted with at least one halogen, or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S; R5 is H or (C1-C3)-alkyl; and R6 is H or (C1-C3)-alkyl.
In some embodiments of the method, le is —N(R4)2 or cyclopropyl; R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholine; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of the method, R1 is —N(R4)2 or cyclopropyl; R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isogninolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more fluorine atoms; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholino; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of the method, R1 is —N(CH3)2, cyclopropyl, or
In some embodiments of the method, R1 is
R3 is naphthalen-1-yl or naphthalen-2-yl; R6 is H, methyl or CD3; and n is 0.
In some embodiments of the method, R1 is
In some embodiments of the method, the compound is
In some embodiments of the method, the compound is
In some embodiments of the method, R1 is —N(R4)2 or cyclopropyl; R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolm-8-yl, or isoqumolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholine; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of the method, R1 is —N(CH3)2 or cyclopropyl; R2 is F; R3 is naphthalen-1-yl or naphthalen-2-yl; and n is 0 or 1.
In some embodiments of the method, the compound is selected from
In some embodiments of the method, the compound is
Some embodiments of the method also include identifying the subject as being in need of treatment for an ASD.
Some embodiments of the method further involve assessing progression or severity of ASD in the subject. In some embodiments, the assessing step is performed after the administering step. In some embodiments, the assessing step is performed before the administering step. In some embodiments the assessing step is performed before and after the administering step.
Some embodiments of the method further involve administering a second composition for use in treating an ASD. In some embodiments, the second composition can include, for example, risperidone, aripiprazole, or both.
The presently-disclosed subject matter further includes a kit that can include a compound or pharmaceutical composition as described herein, packaged together with a device useful for administration of the compound or composition. As will be recognized by those or ordinary skill in the art, the appropriate administration-aiding device will depend on the formulation of the compound or composition that is selected and/or the desired administration site. For example, if the formulation of the compound or composition is appropriate for injection in a subject, the device could be a syringe. For another example, if the desired administration site is cell culture media, the device could be a sterile pipette.
The presently-disclosed subject matter further includes a kit that can include a composition comprising the compound of formula (I), packaged together with a second composition for treatment of ASD. In some embodiments, the second composition can be selected from the group consisting of risperidone, aripiprazole, and combinations thereof.
This Summary describes several embodiments of the presently-disclosed subject matter, and in many cases lists variations and permutations of these embodiments. This Summary is merely exemplary of the numerous and varied embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to other embodiments of the presently-disclosed subject matter, whether listed in this Summary or not. To avoid excessive repetition, this Summary does not list or suggest all possible combinations of such features.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying drawings of which:
The details of one or more embodiments of the presently-disclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and other embodiments, will be evident to those of ordinary skill in the art after a study of the information provided in this document. The information provided in this document, and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood therefrom. In case of conflict, the specification of this document, including definitions, will control.
The presently-disclosed subject matter includes compositions and methods for treating autism spectrum disorder (ASD). The compositions and methods make use of a compound of formula (I).
wherein
X1 is N and X2 is CH;
R1 is —N(R4)2, cyclopropyl, or R5-piperidin-4-yl;
R2 is independently D or halogen;
R3 is naphthyl, quinolinyl isoquinolinyl, or indolyl wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3-alkoxy substituted with at least one D;
R4 is independently H, (C1-C3)-alkyl, (C1-C3)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to Which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S;
R5 is H, (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D;
R6 is H, (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D; and
n is an integer from 0-4; or a pharmaceutically acceptable salt thereof, wherein when R3 is indol-4-yl and n is 0, R1 is not N-methyl-piperazinyl; or a pharmaceutically acceptable salt thereof.
In some embodiments of formula (I), X1 is N and X2 is CH; R1 is —N(R4)2, cyclopropyl, or R5-piperidin-4-yl; R2 is independently D or halogen; R3 is naphthyl, quinolinyl isoquinolinyl, or indolyl wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D; R4 is independently H, (C1-C3)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S; R5 is H, (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D; R6 is H, (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D; and n is an integer from 0-4; or a pharmaceutically acceptable salt thereof.
In some embodiments of formula (I), R3 is naphthyl, quinolinyl. Isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D; and wherein said indolyl is not indol-4-yl; and/or
In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indol-5-yl, wherein said naphthyl, quinolinyl, isoquinolinyl or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D.
In some embodiments of formula (I), R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl, wherein said naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D.
In some embodiments of formula (I), R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl, wherein said naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl is optionally independently substituted with at least one halogen, or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S; R5 is H or (C1-C3)-alkyl; and R6 is H or (C1-C3)-alkyl.
In some embodiments of formula (I), R1 is —N(R4)2 or cyclopropyl; R2 is independently halogen R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl, wherein naphthalen-1-yi, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholine; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of formula (I), R1 is —N(R4)2 or cyclopropyl; R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoqninolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more fluorine atoms; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholino; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of formula (I), R1 is —N(CH3)2, cyclopropyl, or
In some embodiments of formula (I), R1 is
R3 is naphthalen-1-yl or naphthalen-2-yl; R6 is H, methyl or CD3; and n is 0.
In some embodiments of formula (I), The method of claim 9, wherein R1 is
In some embodiments of formula (I), the compound is
In some embodiments of formula (I), the compound is
In some embodiments of formula (I), R1 is —N(R4)2 or cyclopropyl; R2 is independently halogen; R3 is naphthalen-1-yl, naphthalen-2-yl, quinolm-8-yl, or isoqumolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy; R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form NR6-piperazine, piperidine, pyrrolidine, azetidine, or morpholine; R6 is H, methyl or CD3; and n is an integer from 0-2.
In some embodiments of formula (I), R1 is —N(CH3)2 or cyclopropyl; R2 is F; is naphthalen-1-yl or naphthalen-2-yl; and n is 0 or 1.
In some embodiments of formula (I), R1 is —N(CH3)2, cyclopropyl, or
R2 is halogen; R3 is naphthalen-1-yl or naphthalen-2-yl; R6 is H, methyl, or CD3; and n is 1.
In some embodiments of formula (I), R1 is —N(CH3)2, cyclopropyl, or
R2 is halogen; R3 is naphthalen-1-yl or naphthalen-2-yl; R6 is H, methyl; or CD3; and n is 0.
In some embodiments of formula (I), R1 is —N(CH3)2; R3 is naphthalen-1-yl or naphthalen-2-yl; and n is 0.
In some embodiments of formula (I), R1 is —N(CH3)2, cyclopropyl, or N-methyl-piperazinyl; R2 is F; R3 is naphthalen-1-yl or naphthalen-2-yl; and n is 1.
In some embodiments of formula (I), R1 is —N(CH3)2, cyclopropyl, or N-methyl-piperazinyl; R2 is F; R3 is naphthalen-1-yl or naphthalen-2-yl; and n is 0.
In some embodiments of formula (I), the compound is
In some embodiments of formula (I), the compound is
In some embodiments of formula (I), the compound is set forth in Table 1 of international patent application publication no. WO 2014/145485.
In some embodiments of formula (I), X1 is N and X2 is CH, or X1 is CH and X2 is N. In some embodiments of formula (I), R1 is —N(CH3)2, —NH(CH3), or cyclopropyl; R2 is independently halogen; R3 is naphthyl; and n is an integer from 0-4
In some embodiments of formula (I), R1 is —N(R4)2, cyclopropyl; or; R2 is independently halogen; R3 is naphthyl; and n is an integer from 0-4
In some embodiments of formula (I), R2 is independently D or halogen. In some embodiments of formula (I), R2 is halogen. In some embodiments of formula (I), R2 is D, In some embodiments of formula (I), R2 is chlorine or fluorine. In some embodiments of formula (I), R2 is chlorine. In some embodiments of formula (I), R2 is fluorine.
In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy or (C1-C3)-alkoxy substituted with at least one D. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D; and wherein said indolyl is not indol-4-yl. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indol-5-yl, wherein said naphthyl, quinolinyl, isoquinolinyl or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indolyl, wherein said naphthyl, quinolinyl, isoquinolinyl or indolyl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, isoquinolinyl, or indol-5-yl, wherein said naphthyl, quinolinyl, isoquinolinyl or indol-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy. In some embodiments of formula. (I), R3 is naphthyl, quinolinyl, or isoquinolinyl, wherein said naphthyl, quinolinyl or isoquinolinyl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, or isoquinolinyl, wherein said naphthyl, quinolinyl, or isoquinolinyl is optionally independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is naphthyl, quinolinyl, or isoquinolinyl. In some embodiments of formula (I), R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl, wherein said naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoquinolin-5-yl, or indol-5-yl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D. In some embodiments of formula (I). R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, isoqumoHn-5-yl, or indol-5-yl, wherein naphthalen-1-yl, napbthalen-2-yl, quinolin-8-yl, isoqumolin-5-yl, or indol-5-yl is optionally independently substituted with one or more halogen atoms or (C1-C3)-alkoxy. In some embodiments of formula (I), R3 is naphthalen-1-yl, naphiha3en-2-yl, qinnolin-8-yl, isoquinolin-5-yL or indol-5-yl. In some embodiments of formula (I), R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolm-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with at least one halogen or (C1-C3)-alkoxy. In some embodiments of formula (I), R3 is naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yL quinolin-8-yL or isoquinolin-5-yL is optionally independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is naphthalen-1-yl, naphihalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl, wherein naphthalen-1-yl, naphthalen-2-yl, quinolin-8-yl, or isoquinolin-5-yl is optionally independently substituted with one fluorine atom. In some embodiments of formula. (I), R is naphthalen-1-yl or naphthalen-2-yl, optionally substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is naphthalen-1-yl or naphthalen-2-yl.
In some embodiments of formula (I), R3 is
In some embodiments of formula (I), R3 naphthyl, quinolinyl or isoquinolinyl.
In some embodiments of formula (I), R3 naphthyl, independently substituted with one or more halogen atoms. in some embodiments of formula (I), R3 is naphthalen-1-yl or napbthalen-2-yl, independently substituted with one or more halogen atoms. in some embodiments of formula (1), R3 is quinolinyl, independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is quinolinyl In some embodiments of formula (I), R3 is quinolin-8-yL independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is quinolin-8-yl. in some embodiments of formula (I), R3 is isoquinolinyl, independently substituted with one or more halogen atoms. in some embodiments of formula (I), R3 is isoquinolinyl. In some embodiments of formula (I), R3 is isoquinolin-5-yl, independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is isoquinolin-5-yi. In some embodiments of formula (I), R3′ is indolyl. In some embodiments of formula (I), R3 is indolyl, independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is indol-5-yl, independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is indol-5-yl.
In some embodiments of formula (I), R3 is independently substituted with one or more halogen atoms. In some embodiments of formula (I), R3 is independently substituted with one or more D. In some embodiments of formula (I), R3 is independently substituted with one D.
In some embodiments of formula (I), the halogen atom is chlorine or fluorine. In some embodiments of formula (I), the halogen atom is chlorine. In some embodiments of formula (I), halogen atom is fluorine.
In some embodiments of formula (I), R4 is independently H, (C1-C3)-alkyl, (C1-C3)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S. In some embodiments of formula (I), R4 is independently H, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S. In some embodiments of formula (I), R4 is independently H, ((C1-C3)-alkyl, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen. to which they are attached form N-methyl piperazine, piperazine, piperidine, pyrrolidine, azetidine, or morpholine. In some embodiments of formula (I), R4 is independently H, (C1-C3)-alkyl, or each R4 together with the nitrogen to which they are attached form
In some embodiments of formula (I), each R4 together with the nitrogen to which they are attached form
In some embodiments of formula (I), R4 is independently H or methyl. In some embodiments of formula (I), R4 is independently H, methyl or ethyl. In some embodiments of formula (I), R4 is independently methyl or ethyl. In some embodiments of formula (I), R4 is independently methyl. In some embodiments of formula (I), R4 is independently ethyl.
In some embodiments of formula (I), R4 is independently H or CD3. In some embodiments of formula (I), R4 is independently H, CD3 or CH2CD3. In some embodiments of formula (I), R4 is independently CD3 or CH2CD3. in some embodiments of formula (I), R4 is independently CD3. In some embodiments of formula (I), R4 is independently CH2CD3.
In some embodiments of formula (I), R5 is H or (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D. in some embodiments of formula (I), R5 is H or (C1-C3)-alkyl. in some embodiments of formula R5 is H or methyl. In some embodiments of formula (I), R5 is H. In some embodiments of formula (I), R5 is H, methyl or ethyl. In some embodiments of formula (I). R5 is methyl or ethyl in some embodiments of formula (I), R5 is methyl. In some embodiments of formula. (I), R5 is ethyl.
In some embodiments of formula (I), R5 is H or CD3, In some embodiments of formula (I), R5 is CD3 or CH2CD3. In some embodiments of formula (I), R5 is CD3 or CH2CD3. In some embodiments of formula (I), R5 is CD3. In some embodiments of formula (I), R5 is CH2CD3.
In some embodiments of formula (I), R6 is H or (C1-C3)-alkyl, or (C1-C3)-alkyl. substituted with at least one D. in some embodiments of formula (I), R6 is H or (C1-C3)-alkyl. in some embodiments of formula (I), R6 is H or methyl. In some embodiments of formula (I), R6 is H. In some embodiments of formula (I), R6 is H, methyl or ethyl. In some embodiments of formula (I), R6 is methyl or ethyl In some embodiments of formula. (I), R6 is methyl. In some embodiments of formula (I), R6 is ethyl.
In some embodiments of formula (I), R6 is H, methyl or CD3. In some embodiments of formula (I), R6 is II or CD3. In some embodiments of formula (I). R6 is H, CD3 or CH2CD3. In some embodiments of formula (I), R6 is CD3 or CH2CD3. In some embodiments of formula (I), R6 is CD3. In some embodiments of formula (I), R6 is CH2CD3.
In some embodiments of formula (I), n is an integer from 0-4. In some embodiments of formula (I), n is an integer from 0-3. In some embodiments of formula (I), n is an integer from 0-2. In some embodiments of formula (I), n is an integer from 0-1. In some embodiments of formula (I), n is an integer from 1-2. In some embodiments of formula (I), n is 0. In some embodiments of formula (I), n is 1. In some embodiments of formula (I), n is 2.
In some embodiments, R3 is not indolyl. In some embodiments, R3 is not indolyl when n is 0. In some embodiments, R3 is not indol-4-yl. In some embodiments, R3 is not indol-4-yl when n is 0. In some embodiments, R4 is not H or (C1-C3)-alkyl when is indolyl and n is 0. In some embodiments, when R3 is indol-4-yl and n is 0, R1 is not N-methyl-piperazinyl.
The composition disclosed herein may be used for the treatment of autism spectrum disorder (ASD). In some embodiments, there is provided a pharmaceutical composition for use in the treatment of one or more diseases or indications set forth herein, which comprises a compound of formula I, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient.
The term “physiologically functional derivative” means any pharmaceutically acceptable derivative of a compound of the present disclosure. For example, an amide or ester of a compound of the present disclosure, which upon administration to a subject, particularly a mammal, is capable of providing, either directly or indirectly, a compound of the present disclosure of an active metabolite thereof.
Certain compounds of the present disclosure may exist in stereoisomeric forms (e.g., they may contain one or more asymmetric carbon atoms, or they may exhibit cis-trans isomerism), and, the individual stereoisomers and mixtures of these are included within the scope of the present disclosure.
The presently-disclosed subject matter further includes pharmaceutical compositions of the compounds and/or compositions as disclosed herein, and further includes a pharmaceutically-acceptable carrier. In this regard, the term “pharmaceutically acceptable carrier” refers to sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.
The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a frozen or freeze-dried condition requiring only the addition of sterile liquid carrier immediately prior to use.
For oral administration, the compositions can take the form of, for example, tablets or capsules prepared by a conventional technique with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods known in the art.
Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner.
The compounds can also be formulated as a preparation for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).
The compounds can also be formulated in rectal compositions (e.g., suppositories or retention enemas containing conventional suppository bases such as cocoa butter or other glycerides), creams or lotions, or transdermal patches.
The presently-disclosed subject matter includes a method for treating an autism spectrum disorder (ASD). In some embodiments the method comprises administering a compound, including one of the compounds described herein, to a subject in need thereof. In some embodied methods a plurality of compounds according the present disclosure are administered simultaneously or in a predetermined sequence. In some embodiments the method comprises administering to a subject in need of treatment an effective amount of a composition comprising the compound of formula (I).
As used herein, autism spectrum disorder (ASD) refers to the disorder(s) as defined in the fifth edition of the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-5) characterized by communication deficits, such as responding inappropriately in conversations, misreading nonverbal interactions, or having difficulty building friendships appropriate to their age. In addition, subjects with ASD may be overly dependent on routines, highly sensitive to changes in their environment, or intensely focused on inappropriate items. As recognized in the art, the symptoms of people with ASD will fall on a continuum, with some individuals showing mild symptoms and others having much more severe symptoms.
Diagnostic criteria for ASD include deficits in social-emotional reciprocity (ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions) deficits in nonverbal communicative behaviors used for social interaction (ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication); deficits in developing, maintaining, and understanding relationships (ranging, for example, from difficulties adjusting behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; to absence of interest in peers); stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple motor stereotypes, lining up toys or flipping objects, echolalia, idiosyncratic phrases); insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior (e.g., extreme distress at small changes, difficulties with transitions, rigid thinking patterns, greeting rituals, need to take same route or eat same food every day); highly restricted, fixated interests that are abnormal in intensity or focus (e.g., strong attachment to or preoccupation with unusual objects, excessively circumscribed or perseverative interests); and hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment (e.g. apparent indifference to pain/temperature, adverse response to specific sounds or textures, excessive smelling or touching of objects, visual fascination with lights or movement).
For purposes of the methods and composition described herein, ASD is also inclusive of Social (Pragmatic) Communication Disorder, as well as disorders associated with ASD under DSM-4, including autistic disorder, Asperger's disorder, childhood disintegrative disorder, and pervasive developmental disorder. Accordingly the methods and compositions described herein can be used for treatment of one or more of these ASD disorders.
In connection with the methods and compositions disclosed herein, as will be understood by one of ordinary skill in the art upon study of the present document, in some embodiments it can be useful to identify or specify ASD subjects with hyperserotonemia (whole blood levels of serotonin significantly above that found in healthy controls); and in some embodiments it can be useful to identify or specify ASD subjects with brain elevations in levels or sensitivity of 5HT2A or 5HT1A receptors.
Unless otherwise indicated, the term “administering” is inclusive of all means known to those of ordinary skill in the art for providing a preparation to a subject, including administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, intravitreous administration, intracameral administration, posterior sub-Tenon administration, posterior juxtascleral administration, subretinal administration, suprachoroidal administration, cell-based administration or production, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and/or subcutaneous administration. Administration can be continuous or intermittent. A preparation can be administered therapeutically; that is, administered to treat an existing condition of interest. A preparation can be administered prophylactically; that is, administered for prevention of a condition of interest.
As will be recognized by one of ordinary skill in the art, the terms “suppression,” “suppressing,” “suppressor,” “inhibition,” “inhibiting” or “inhibitor” do not refer to a complete elimination of angiogenesis in all cases. Rather, the skilled artisan will understand that the term “suppressing” or “inhibiting” refers to a reduction or decrease in angiogenesis. Such reduction or decrease can be determined relative to a control. In some embodiments, the reduction or decrease relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease.
As used herein, the terms “treatment” or “treating” relate to any treatment of a condition of interest, including but not limited to prophylactic treatment and therapeutic treatment. As such, the terms treatment or treating include, but are not limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a condition of interest; ameliorating or relieving symptoms associated with a condition of interest; and causing a regression of the condition of interest or one or more of the symptoms associated with the condition of interest.
In some embodiments of the method, treatment reduces at least one of the following: deficits in social-emotional reciprocity; deficits in nonverbal communicative behaviors used for social interaction; deficits in developing, maintaining, and understanding relationships stereotyped or repetitive motor movements, use of objects, or speech; insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior; highly restricted, fixated interests that are abnormal in intensity or focus; and hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment.
In some embodiments a subject will be administered an effective amount of at least one compound and/or composition provided in the present disclosure. In this respect, the term “effective amount” refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
Some embodiments of the method can further include administering a second composition for treatment of ASD. In some embodiments, the second composition can be selected from the group consisting of risperidone, aripiprazole, and an IL-6 receptor antagonist
The terms “subject” or “subject in need thereof” refer to a target of administration, which optionally displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. A patient refers to a subject afflicted with a disease or disorder. The term “subject” includes human and veterinary subjects.
Some embodiments of the method further involve assessing progression or severity of ASD in the subject. In some embodiments, the assessing step is performed after the administering step. In some embodiments, the assessing step is performed before the administering step. In some embodiments the assessing step is performed before and after the administering step.
The presently-disclosed subject matter further includes a kit that can include a compound or pharmaceutical composition as described herein, packaged together with a device useful for administration of the compound or composition. As will be recognized by those or ordinary skill in the art, the appropriate administration-aiding device will depend on the formulation of the compound or composition that is selected and/or the desired administration site. For example, if the formulation of the compound or composition is appropriate for injection in a subject, the device could be a syringe. For another example, if the desired administration site is cell culture media, the device could be a sterile pipette.
The presently-disclosed subject matter further includes a kit that can include a composition comprising the compound of formula. (I), packaged together with a second composition for treatment of ASD. in some embodiments, the second composition can be selected from the group consisting of risperidone, aripiprazole, and an IL-6 receptor antagonist.
Additionally, the present disclosure provides uses of a compound of formula (I), a salt, a solvate, or physiological derivative thereof in the preparation or manufacture of a drug and/or medicine, especially a medicine for the treatment of at least one autism spectrum disorder in a mammal.
The present disclosure is directed, in certain embodiments, to the use of a compound and/or composition to cause a pharmacological reversal of at least one autism spectrum disorder-related social deficit. Meanwhile, in some embodiments, the present disclosure provides a CNS-penetrant p38α MAPK inhibitor for the prevention, treatment and/or reduction of an autism spectrum disorder (ASD).
In some embodiments, the present disclosure provides compositions and/or methods whereby antagonism of p38 MAPK signaling prevents, corrects, reduces and/or treats at least one symptom associated with at least one autism spectrum disorder. In some embodiments, administration of a compound and/or composition of the present disclosure antagonizes p38 MAPK signaling. In certain embodiments, the at least one symptom associated with an autism spectrum disorder is a social defect and/or social deficit.
In some embodiments, the present disclosure provides compositions and/or methods whereby antagonism of p38 MAPK signaling prevents, corrects, reduces and/or treats receptor hypersensitivity. In certain embodiments, the present disclosure provides compositions and/or methods whereby antagonism of p38 MAPK signaling prevents, corrects, reduces and/or treats altered and/or irregular social behavior. And in certain embodiments, the present disclosure provides compositions and/or methods for preventing, correcting and/or treating a particular phenotype using a p38 MAPK inhibitor.
In some embodiments, the present disclosure provides a composition comprising at least one CNS-penetrant, such as a p38 MAPKα inhibitor. In certain embodiments, the present disclosure provides a composition comprising a CNS-penetrant, selective p38 MAPKα inhibitor MW108 for use in reversing, preventing, reducing and/or treating at least one social deficit in at least one subject having at least one symptom of ASD.
While the terms used herein are believed to be well understood by those of ordinary skill in the art, certain definitions are set forth to facilitate explanation of the presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong.
Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.
As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, Biochem. (1972) 11(9):1726-1732).
Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently-disclosed subject matter, representative methods, devices, and materials are described herein.
Following long-standing patent law convention, the terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a cell” includes a plurality of such cells, and so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently-disclosed subject matter.
As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples. The following examples may include compilations of data that are representative of data gathered at various times during the course of development and experimentation related to the present invention.
The inventors of the present application have demonstrated that CNS-penetrant, selective p38 MAPKα inhibitors can reverse social deficits in an animal model of autism that was produced to express a genetic variant (SERT Ala56) that was identified in multiple ASD subjects.
In prior ASD genetic studies, 5 rare, genetic variants were discovered in the SLC6A4 gene encoding the 5-HT transporter (SERT) that lead to elevated SERT function (Sutcliffe et al. 2005). In vivo expression of SERT Ala56 in a knock-in mouse model results in multiple ASD-like phenotypes, including hyperserotonemia, repetitive behaviors and deficits in social interactions and communication (Veenstra-VanderWeele et al, 2012).
Notably, SERT Ala56 mice display a p38 MAPK-dependent hyperphosphorylation of SERT within the CNS, consistent with the prior findings that activation of p38α MAPK elevates SERT function in vitro and in vivo (Zhu et al. 2006, Zhu et al. 2010). These findings suggest that the hyperfunction of SERT Ala56 and resulting physiological and behavioral phenotypes are due to unopposed p38α MAPK phosphorylation of the transporter.
This and other genetics-based ASD animal models provide an important opportunity to drive translational research and drug development. A common feature of various animal models of ASD involves an engagement of altered immune system function and signaling that can drive various ASD-like behavioral deficits.5-7 Based upon findings of a role for immune system signaling in the regulation of CNS 5-HT inactivation, the present inventors have oriented significant efforts to determine how inflammatory signaling, mediated by p38α MAPK, regulates serotonin (5-HT) neuron-dependent signaling and behavior.
The present inventors contemplated that pharmacologic inhibition of p38α MAPK could attenuate or reverse one or more phenotypes in the SERT Ala56 model. Recently, a series of highly selective, brain-penetrant, p38 MAPK inhibitors were developed with evidence accruing to support utility in brain injury models (See, e.g., Watterson et al. 2014; International Patent Application Publication No. WO 2014/145485). In this example the present inventors report efforts to reverse ASD features of adult SERT Ala56 mice with selective p38 MAPK inhibitors, including the compounds referred to herein as MW108 and MW150.
The studies described herein are aimed at the reversal of ASD-like phenotypes in a construct and face valid genetic model of ASD, the 5-HT transporter (SERT) Ala56 knock in mouse. In addition to exhibiting ASD-like behavioral phenotypes, these mice have been found to display p38 MAPK-dependent increases in SERT phosphorylation,8 an effect previously linked to the activity of the transporter.8, 9 These studies make use of selective CNS-penetrant, p38α MAPK inhibitors, including the compounds referred to herein as MW108 and MW150. Characterization of the consequences of the inhibition of p38α MAPK by these selective inhibitors is useful for identifying compounds for use in drug development in the treatment of ASD.
Sites of expression required to produce immune, behavioral and gastrointestinal phenotypes of Maternal immune activation (MIA) and SERT Ala56 models were determined using conditional elimination of IL-1R and p38α MAPK. Il1r1loxP/loxP mice and ePET1-Cre:p38α MAPKloxP/loxP mice were generated to afford serotonin neuron-specific elimination of receptor and kinase, respectively.
As shown in
The ePET1-Cre:p38α MAPKloxP/loxP model was generated. With reference to
Studies were conducted to determine whether pharmacological targeting of inflammatory cytokine (IL-6) or p38α MAPK signaling can prevent or reverse the autism-like phenotypes of the SERT Ala56 mice or mice born to dams subjected to immune system activation during pregnancy. Exemplary compounds from a series of specific CNS penetrant p38α MAPK inhibitors (MW108 and MW150 (
As shown in
As described herein, SERT Ala56 mice have deficits in social behaviors in the Tube Test for Social Dominance. Studies were also conducted to determine the effect of specific p38 MAPK inhibitors on social deficits in the animal of ASD. Mice were treated with either saline or a specific p38 MAPK inhibitor for one week.
With reference to
Turning now to
Similarly, with reference to
With reference to
Similarly, both drugs normalize 5-HT1A receptor hypersensitivity seen in adult SERT Ala56 mice as monitored by 8-OHDPAT induced hypothermia responses. With reference to
As shown in
The data also show that the actions of chronic MW108 administration do not arise as a consequence of changes in steady state 5-HT or SERT levels, but rather reflect changes in SERT activity that alters extracellular 5-HT availability and signaling. With reference to
As shown in
Finally,
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference, including the references set forth in the following list:
It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the subject matter disclosed herein. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
This application claims priority from U.S. Provisional Application Ser. No. 62/081,002 filed Nov. 17, 2014, the entire disclosure of which is incorporated herein by this reference.
This invention was made with government support under grant number MH096972 awarded by the National Institutes of Health. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
62081002 | Nov 2014 | US |